RKDANasdaqCrude Petroleum & Natural GasFiscal year ends December 31
Arcadia Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.14−0.02 (-12.01%)
Close on Oct 19, 2026
- Market cap
- $433.92K
- P/E (TTM)
- –
- Dividend yield
- –
Arcadia Biosciences, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | $4.86M | $5.01M | $4.44M | $6.42M | $6.59M | $1.04M | $814.00K | $657.00K | $514.00K | – | 100.0% | -3.1% |
| License | $0 | $7.00K | $17.00K | $879.00K | $17.00K | $6.80M | $67.00K | $150.00K | $1.47M | – | 0.0% | -100.0% |
| Royalty | $0 | $26.00K | $0 | $117.00K | $176.00K | $83.00K | – | – | – | – | 0.0% | -100.0% |
| Contract Research And Government Grants | – | – | – | – | – | $106.00K | $288.00K | $657.00K | $2.04M | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $4.86M | $4.90M | $4.16M | $6.30M | $6.00M | $761.00K | $722.00K | $1.17M | $1.59M | $2.72M | 100.0% | -0.9% |
| Canada | $0 | $109.00K | $291.00K | $194.00K | $503.00K | $354.00K | $258.00K | $91.00K | $181.00K | $202.00K | 0.0% | -100.0% |
| India | $0 | $7.00K | $7.00K | $7.00K | $7.00K | $100.00K | $7.00K | $90.00K | $1.06M | – | 0.0% | -100.0% |
| Argentina | $0 | $26.00K | $0 | $862.00K | $26.00K | $6.68M | – | – | – | – | 0.0% | -100.0% |
| France | – | – | – | – | – | – | – | – | $220.00K | $18.00K | – | – |
| Africa | – | – | – | – | – | $106.00K | $182.00K | $115.00K | $315.00K | $353.00K | – | – |
| Belgium | – | – | – | – | – | – | – | – | $72.00K | – | – | – |
| China | – | – | – | – | – | – | – | – | $586.00K | – | – | – |
| Austria | – | – | – | – | – | $32.00K | – | – | – | – | – | – |
| United Kingdom | – | – | – | – | $16.00K | – | – | – | – | – | – | – |
| Spain | – | – | – | – | $225.00K | – | – | – | – | – | – | – |
| Germany | – | – | $0 | $57.00K | – | – | – | – | – | – | – | – |
From the segment and revenue-disaggregation notes of Arcadia Biosciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.